Twist Bioscience Q3 2024 Adj. EPS $(0.70) Beats $(0.77) Estimate, Sales $81.464M Beat $77.404M Estimate
Portfolio Pulse from Benzinga Newsdesk
Twist Bioscience reported its Q3 2024 financial results, with an adjusted EPS of $(0.70) beating the estimate of $(0.77) and sales of $81.464 million surpassing the $77.404 million estimate.
August 02, 2024 | 11:32 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Twist Bioscience's Q3 2024 financial results exceeded expectations, with an adjusted EPS of $(0.70) beating the $(0.77) estimate and sales of $81.464 million surpassing the $77.404 million estimate.
Twist Bioscience's better-than-expected earnings and sales figures are likely to positively impact its stock price in the short term. Beating both EPS and sales estimates typically boosts investor confidence and can lead to a stock price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100